This HTML5 document contains 59 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/domain/vavai/projekt/
n5http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n16http://linked.opendata.cz/resource/domain/vavai/subjekt/
n13http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00023001%3A_____%2F12%3A00056023%21RIV13-MZ0-00023001/
n10http://linked.opendata.cz/ontology/domain/vavai/
shttp://schema.org/
rdfshttp://www.w3.org/2000/01/rdf-schema#
skoshttp://www.w3.org/2004/02/skos/core#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/
n17http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n12http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n19http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n15http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n11http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n9http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n6http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n14http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00023001%3A_____%2F12%3A00056023%21RIV13-MZ0-00023001
rdf:type
n10:Vysledek skos:Concept
rdfs:seeAlso
http://versita.metapress.com/content/j4541166l31p1028/fulltext.pdf
dcterms:description
Statins have become a cornerstone of cardiovascular prevention. However, their lipid lowering efficacy and, thus also, impact on event risk reduction, differ substantially between individuals. The major part of this inter-individual difference can be explained by genetic factors. Using the GWA approach, candidate genes that may modify the response to statin treatment have been detected. Variants rs646776 (CELSR2/PSRC1/SORT1), rs16996148 (CILP2/PBX4), rs11206510 (PCSK9) and rs693 (APOB) were analysed in 370 (146 males) dyslipidemic patients treated with statins (46.6% simvastatin, 41.5% atorvastatin, 11.9% lovastatin, 10 or 20 mg/day) and 470 normolipidemic controls (188 males). Lipid levels were available prior to and after 8-12 weeks of therapy. There was a significant decrease both in the total (7.36 +/- 1.28 -> 5.43 +/- 1.01 mmol/l) and LDL-cholesterol (4.72 +/- 1.35 -> 3.19 +/- 0.98 mmol/l) after treatment. The genotype frequencies of the three SNPs differed between patients and controls (rs646776, rs16996148, rs693). The carriers of the minor rs599838 genotype had a significantly lower response to statin treatment compared to common homozygotes (LDL-cholesterol, Delta-20.3% vs. Delta-32.0%). No other significant associations with lipid changes were detected. Together with variations of other, multiple gene loci the variant at CELSR2/PSRC1/SORT1 gene cluster may be useful for individualization of statin treatment leading to better outcomes of the treatment. Statins have become a cornerstone of cardiovascular prevention. However, their lipid lowering efficacy and, thus also, impact on event risk reduction, differ substantially between individuals. The major part of this inter-individual difference can be explained by genetic factors. Using the GWA approach, candidate genes that may modify the response to statin treatment have been detected. Variants rs646776 (CELSR2/PSRC1/SORT1), rs16996148 (CILP2/PBX4), rs11206510 (PCSK9) and rs693 (APOB) were analysed in 370 (146 males) dyslipidemic patients treated with statins (46.6% simvastatin, 41.5% atorvastatin, 11.9% lovastatin, 10 or 20 mg/day) and 470 normolipidemic controls (188 males). Lipid levels were available prior to and after 8-12 weeks of therapy. There was a significant decrease both in the total (7.36 +/- 1.28 -> 5.43 +/- 1.01 mmol/l) and LDL-cholesterol (4.72 +/- 1.35 -> 3.19 +/- 0.98 mmol/l) after treatment. The genotype frequencies of the three SNPs differed between patients and controls (rs646776, rs16996148, rs693). The carriers of the minor rs599838 genotype had a significantly lower response to statin treatment compared to common homozygotes (LDL-cholesterol, Delta-20.3% vs. Delta-32.0%). No other significant associations with lipid changes were detected. Together with variations of other, multiple gene loci the variant at CELSR2/PSRC1/SORT1 gene cluster may be useful for individualization of statin treatment leading to better outcomes of the treatment.
dcterms:title
Variant within CELSR2/PSRC1/SORT1, but not within CILP2/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy Variant within CELSR2/PSRC1/SORT1, but not within CILP2/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy
skos:prefLabel
Variant within CELSR2/PSRC1/SORT1, but not within CILP2/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy Variant within CELSR2/PSRC1/SORT1, but not within CILP2/PBX4, PCSK9 and APOB genes, has a potential to influence statin treatment efficacy
skos:notation
RIV/00023001:_____/12:00056023!RIV13-MZ0-00023001
n10:predkladatel
n16:ico%3A00023001
n4:aktivita
n11:P n11:I
n4:aktivity
I, P(NS10579)
n4:cisloPeriodika
1
n4:dodaniDat
n14:2013
n4:domaciTvurceVysledku
n5:3241513 n5:6873472 n5:4176456 n5:6198325 n5:6513832
n4:druhVysledku
n6:J
n4:duvernostUdaju
n19:S
n4:entitaPredkladatele
n13:predkladatel
n4:idSjednocenehoVysledku
177017
n4:idVysledku
RIV/00023001:_____/12:00056023
n4:jazykVysledku
n15:eng
n4:klicovaSlova
APOB; PCSK9; CILP2/PBX4; CELSR2/PSRC1/SORT1; treatment efficacy; pharmacogenetics; gene variants; statins; dyslipidemia
n4:klicoveSlovo
n12:treatment%20efficacy n12:PCSK9 n12:gene%20variants n12:APOB n12:dyslipidemia n12:statins n12:CILP2%2FPBX4 n12:CELSR2%2FPSRC1%2FSORT1 n12:pharmacogenetics
n4:kodStatuVydavatele
CZ - Česká republika
n4:kontrolniKodProRIV
[8A41EC775216]
n4:nazevZdroje
Journal of applied biomedicine
n4:obor
n9:FA
n4:pocetDomacichTvurcuVysledku
5
n4:pocetTvurcuVysledku
9
n4:projekt
n20:NS10579
n4:rokUplatneniVysledku
n14:2012
n4:svazekPeriodika
10
n4:tvurceVysledku
Lánská, Věra Vrablik, Michal Prusikova, Martina Ceska, Richard Zlatohlavek,, Lukas Adámková, Věra Dlouhá, Dana Rynekrová, Jitka Hubáček, Jaroslav
n4:wos
000300403600003
s:issn
1214-021X
s:numberOfPages
10
n17:doi
10.2478/v10136-012-0001-3